European review for medical and pharmacological sciences · 2022
Awareness of chronic hepatitis C in the Western Black Sea Region.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maria Alexandre Thibault, Maquart Marianne, Makinson Alain, Flusin Olivier, Segondy Michel, Leparc-Goffart Isabelle, Le Moing Vincent, Foulongne Vincent
Аннотация
OBJECTIVE: Chronic hepatitis C (CHC) can be cured with oral antivirals. Awareness of CHC is a substantial barrier to the World Health Organization's goal of eradicating HCV by 2030. This study aimed at evaluating CHC awareness among different departments in a Western Black Sea Region University Hospital.
PATIENTS AND METHODS: Anti-HCV and HCV RNA test results of all patients admitted to our center for whatever reason and who underwent anti-HCV screening between January 2017 and January 2022 were analyzed. CHC awareness has been defined as the presence of HCV RNA testing for anti-HCV positives.
RESULTS: Of the 63,963 patients who underwent anti-HCV testing, anti-HCV positivity was observed in 2%. HCV RNA was tested in 647 (48.8%) patients who had tested positive for anti-HCV. The HCV RNA was positive in 212 (32.7%) patients tested. Only 66 (29.7%) of those with positive HCV RNA test results had received antiviral therapy. The distribution of HCV RNA testing rates for patients with positive anti-HCV by different departments were as follows: 33% (n=78/232) in medical inpatient clinics, 78% (n=539/685) in medical outpatient clinics, 7% (n=16/223) in surgical inpatient clinics, 7% (n=14/183) in surgical outpatient clinics, and 0% in the emergency department.
CONCLUSIONS: The prevalence of anti-HCV positivity in our region was 2%. Less than half of the patients tested for anti-HCV had HCV RNA testing, and less than a third of the HCV RNA-positive patients received antiviral therapy. To meet the WHO's HCV eradication target by 2030, it is necessary to increase physicians' awareness of CHC.
PATIENTS AND METHODS: Anti-HCV and HCV RNA test results of all patients admitted to our center for whatever reason and who underwent anti-HCV screening between January 2017 and January 2022 were analyzed. CHC awareness has been defined as the presence of HCV RNA testing for anti-HCV positives.
RESULTS: Of the 63,963 patients who underwent anti-HCV testing, anti-HCV positivity was observed in 2%. HCV RNA was tested in 647 (48.8%) patients who had tested positive for anti-HCV. The HCV RNA was positive in 212 (32.7%) patients tested. Only 66 (29.7%) of those with positive HCV RNA test results had received antiviral therapy. The distribution of HCV RNA testing rates for patients with positive anti-HCV by different departments were as follows: 33% (n=78/232) in medical inpatient clinics, 78% (n=539/685) in medical outpatient clinics, 7% (n=16/223) in surgical inpatient clinics, 7% (n=14/183) in surgical outpatient clinics, and 0% in the emergency department.
CONCLUSIONS: The prevalence of anti-HCV positivity in our region was 2%. Less than half of the patients tested for anti-HCV had HCV RNA testing, and less than a third of the HCV RNA-positive patients received antiviral therapy. To meet the WHO's HCV eradication target by 2030, it is necessary to increase physicians' awareness of CHC.